Efficacy of opicapone in Parkinson’s disease patients according to baseline pramipexole use: a post-hoc analysis from combined BIPARK-I and II.
Objective: To evaluate opicapone’s (OPC) efficacy in levodopa-treated Parkinson’s Disease (PD) patients with or without concurrent pramipexole use (CPU). Background: OPC, a once-daily COMT inhibitor,…Impact of oral COMT-inhibitors on gut microbiota and biologically active microbial metabolites in patients with Parkinson’s Disease
Objective: To investigate if we were able to reproduce our previous findings in an independent patient cohort and whether such a correlation also exists in…Efficacy of opicapone in Parkinson’s disease patients according to baseline rasagiline use: a post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate opicapone’s (OPC) efficacy in levodopa-treated Parkinson’s Disease (PD) patients with or without concurrent rasagiline use (CRU). Background: OPC, a once-daily COMT inhibitor,…Opicapone and levodopa-carbidopa intestinal gel infusion: a cost saving analysis in the United Kingdom
Objective: To investigate whether the use of Opicapone as an add-on therapy to levodopa-carbidopa intestinal gel (LCIG) infusion in advanced Parkinson’s disease (PD) reduces the…Effect of Once-Daily Opicapone on the Pharmacokinetics of Repaglinide
Objective: To evaluate the effect of once-daily administration of opicapone 50 mg on the pharmacokinetics (PK) of repaglinide. Background: Opicapone, a highly selective catechol-O-methyltransferase (COMT)…Impact of repeated oral administration of Opicapone on the plasma pharmacokinetics of levodopa
Objective: To examine the inhibitory effect of COMT on the plasma pharmacokinetics of levodopa resulting from repeated, once daily, oral administration of an Opicapone (OPC)…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline MAO-B inhibitors use: post-hoc analysis from double-blind combined BIPARK-I and II data
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…Opicapone improves motor and non-motor wearing off symptoms in Parkinson’s disease: an observational real-world study
Objective: To assess the impact of opicapone - a third generation COMT Inhibitor - on motor and non-motor wearing off symptoms in patients suffering from…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline disease severity: post-hoc analysis from double-blind combined BIPARK-I and II data
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…First year of Opicapone for Advanced Parkinson Disease: real-life experience in a single Movement Disorders Unit
Objective: The aim of the study is to evaluate opicapone in an heterogeneous patient population, reflecting daily clinical practice. Background: Opicapone is a new COMT-inhibitor indicated…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 12
- Next Page »